Skip to main content
Download PDF

Gut microbiota mediated the therapeutic efficiency of Simiao decoction in the treatment of gout arthritis mice

BMC Complementary Medicine and Therapies volume 23, Article number: 206 (2023) Cite this article

A Correction to this article was published on 17 July 2023

This article has been updated

Abstract

Background

Gut microbiota plays a significant role in the development and treatment of gouty arthritis. Simiao decoction has been shown to alleviate gouty arthritis by inhibiting inflammation, regulating NLRP3 inflammasome, and altering gut microbiota. However, there is no evidence to prove whether gut microbiota directly mediates the therapeutic efficiency of Simiao decoction in treating gout arthritis.

Methods

In this study, fecal microbiota transplantation (FMT) was used to transfer the gut microbiota of gout arthritis mice treated with Simiao decoction or allopurinol to blank gout arthritis mice, in order to investigate whether FMT had therapeutic effects on gout arthritis.

Results

Both Simiao decoction and allopurinol effectively reduced the levels of serum uric acid, liver XOD activity, foot thickness, serum IL-1β, and G-CSF in gout arthritis mice. However, Simiao decoction also had additional benefits, including raising the pain threshold, reducing serum TNF-α and IL-6, alleviating gut inflammation, and repairing intestinal pathology, which were not observed with allopurinol treatment. Moreover, Simiao decoction had a greater impact on gut microbiota than allopurinol, as it was able to restore the abundance of phylum Proteobacteria and genus Helicobacter. After transplantation into gout arthritis mice, gut microbiota altered by Simiao decoction exhibited similar therapeutic effects to those of Simiao decoction, but gut microbiota altered by allopurinol showed no therapeutic effect.

Conclusions

These findings demonstrates that Simiao decoction can alleviate gout arthritis symptoms by regulating gut microbiota.

Peer Review reports

Introduction

Gout is a prevalent type of inflammatory arthritis that occurs due to the deposition of monosodium urate (MSU). This condition is directly linked to hyperuricemia, which is caused by the disruptions in purine metabolism and/or decreased uric acid excretion [1]. In Mainland China, the prevalence of gout is 1.6%, with higher rates observed in males (1.9%) than in females (0.5%) [2]. Gout arthritis is characterized by recurrent attacks and typically involve joint inflammation, including redness, swelling, heat, and pain, with acute attacks causing severe pain [3]. The inflammatory cascade triggered by MSU crystals is the main cause of the acute symptoms of gout, and the NLRP3 inflammasome pathway is primarily responsible for MSU-induced cellular inflammation [4]. MSU crystal deposition in the joints activates the NLRP3 inflammasome, leading to the maturation and release of cytokines such as IL-1β and IL-18, results in the gout arthritis flare-ups [4].

Cumulative research has consistently demonstrated the disturbances in gut microbiota among gout patients [5, 6] and animal models [7, 8]. Furthermore, modifying gut microbiota has been found to affect gout arthritis symptoms [9, 10]. The reason for this may be attributed to gut microbiota’s role in regulating the activation of NLRP3 inflammasome [11, 12] and uric acid metabolism [13, 14]. Severe drugs used in gout arthritis therapy have been shown to effectively alter the gut microbiota [15, 16]. Simiao decoction, a classical traditional Chinese medicine formula, is widely used for gout arthritis therapy in clinical practice [17]. It has been reported to be both effective and safe in treating gout patients [18,19,20]. In gout arthritis or hyperuricemia mouse models, Simiao decoction can reduce renal urate transporters, enhance antioxidant enzymes activities, inhibit NLRP3 inflammasome, and decrease serum UA and liver XOD levels [21,22,23]. In our previous study, we demonstrated that Simiao decoction can alleviate gout arthritis symptoms by modulating pro-inflammatory cytokines and gut microbiota in gouty arthritis mice [24]. However, the previous study only established a correlation between gut microbiota and the therapeutic effect of Simiao decoction in treating gout arthritis, it did not prove evidence of the direct involvement of gut microbiota in Simiao decoction’s efficacy against gout arthritis.

To further clarify the role of gut microbiota in treating gout arthritis by Simiao decoction, we conducted a fecal microbiota transplantation (FMT) study by transplanting fresh feces from Simiao decoction-treated gout mice into untreated gout arthritis mice. This allowed us to examine the therapeutic effects of Simiao decoction-altered gut microbiota. Allopurinol was selected as the control drug for Simiao decoction, since it was a well-established and widely used medication for gout arthritis treatment in clinical trials.

Materials and methods

Animals

Male specific pathogen-free (SPF) C57BL/6 mice (4 weeks old, weighing 15 ± 3 g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. and housed in the Zhejiang Chinese Medical University laboratory animal research center under SPF conditions. All animal experiments were approved by the Ethics Committee of Zhejiang Chinese Medical University (approval number 20210816-12). The mice were maintained under a 12 h/12 h light/dark cycle with constant temperature (25 ± 1 °C) and humidity (50 ± 5%), with ad libitum access to food and water. All protocols in this study were carried out in accordance with relevant guidelines and regulations for using animals in compliance with the ARRIVE guidelines (https://arriveguidelines.org).

Preparation of Simiao decoction

Simiao decoction was composed of Atractylodes lancea (Thunb.) DC. (12 g), Phellodendron amurense Rupr. (12 g), Achyranthes bidentata Blume (12 g) and Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf (30 g), which were purchased from Zhejiang Chinese Medical University Medicine Yinpian Factory (Hangzhou, China) and authenticated by the authors. A voucher specimen (No.20,200,305) has been deposited at the Institute of Basic Research in Clinical Medicine of Zhejiang Chinese Medical University (Hangzhou, China).

Study design

After 7 days of environmental adaptation and 7 days of cage acclimatization, male C57BL/6 mice (6 weeks old) were randomly assigned to six groups (N = 6 mice/group): (1) control group (CT) fed a normal diet; (2) gout arthritis group (MT) was fed a high purine diet (10% yeast extract) and received injections of monosodium urate (MSU) crystals (25 mg/mL in PBS solution/mouse per 10 days) into the right foot joint for a duration of 35 days; (3) Simiao decoction group (SM), where gout arthritis mice were orally administered 8.0 g/kg of Simiao decoction daily after the establishment of the gout arthritis model from day 14; (4) FSM group, where gout arthritis mice were given 200 µL/day aliquot of fresh fecal suspensions daily (collected from the mice of SM group daily) from day 17; (5) allopurinol group (AP), where gout arthritis mice were orally administered 30 mg/kg of allopurinol daily after the establishment of gout arthritis model from day 14; and (6) FAP group, where gout arthritis mice were given 200 µL/day aliquot of fresh fecal suspensions daily (collected from the mice of AP group daily) from day 17. The experimental flow and grouping information were presented in Fig. 1.

Fig. 1
figure 1

Overview of experimental schedule (A) and grouping information (B) in the study. CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice; FMT, fecal microbiota transplantation; MSU, monosodium urate crystal

Full size image

Simiao decoction was prepared according to the method described by Lin et al. [24]. The dosage of Simiao decoction for adult is 66 g (total raw materials)/day, and for mice, it is 8.0 g/kg/day, calculated by converting the human dosage to that of mice according to their respective body surface areas, in accordance with Chinese Medicine Pharmacology Research Technology. Fresh feces were collected daily from donor mice as follows: The mouse was fixed and its tail was lift. The lower abdomen of the mouse was pressed with fingers, and the fresh feces were collected in a sterile micro-centrifuge tube. The fecal suspensions were resuspended in 5 times (weight/volume) phosphate-buffered saline solution, passed through a 20-mm filter to remove large particulate, and transferred into the receptor mice. Throughout the trial, all mice were weighed each week, and the drug doses were adjusted accordingly.

At the end of the trial (day 42), the mice were anaesthetised with 3% pentobarbital sodium at a dosage of 40 mg/kg via intraperitoneal injection and sacrificed using cervical dislocation. Blood samples were obtained from the eye socket vein of each mouse, then centrifuged at 3000 rpm for 10 min at 4 oC for serum. Fecal material was removed from the colon and stored at -80 °C for further analysis. Colon tissues were separated into two sections, one part was fixed in 4% formalin for histological analysis, while the other was rapidly snap-frozen in liquid nitrogen and stored at -80 °C for the determination of proinflammatory cytokines. Moreover, liver tissues were also immediately snap-frozen in liquid nitrogen and stored at -80 °C until assessing xanthine oxidase (XOD) activity.

MSU crystal preparation and injection

The method for preparing of MSU crystals followed previously published protocols [7]. Monosodium urate (800 mg) was dissolved in 155 mL of boiling milli-Q water containing 5 mL of NaOH. The solution was adjusted to pH 7.2 and cooled gradually by constant stirring at room temperature. The crystals were collected by centrifugation at 3000 g for 2 min at 4 °C), then evaporated and sterilized by heating at 180 °C for 2 h. The MSU crystals were stored in sterile microtubes until use.

To induce joint inflammation, each mouse was injected with MSU (1.0 mg/40 µL) into the right foot joint via intra-articular (i.a.) injection under isoflurane anesthesia. As a blank control, 40 µL of PBS solution was injected into the right foot joint.

Evaluation of foot thickness and pain threshold

The thickness of each mouse’s foot was measured using a caliper (Meinaite, Germany) before the stimulus and 48 h after i.a. administration of MSU, with foot swelling was expressed as the ratio of the difference between the thickness at 48 h and the thickness at time zero. To quantify foot pain, the mechanical withdrawal threshold (MWT) was measured using von Frey hairs (Stoelting, Wood Dale, IL) and the up-and-down method [25]. Mice were individually placed in testing chambers with metal mesh floors for at least 30 min for acclimation before testing in a quiet, temperature-controlled room. Each test began with a force of 0.16 g delivered perpendicularly to the central plantar surface of either hind paw for 3 s with a hair. Positive responses included sudden paw withdrawal, flinching, or paw licking, and no response was considered negative. The threshold force required to elicit withdrawal (50% hind paw withdrawals) was determined for right hind paws [26]. The minimum force that could provoke at least three withdrawal responses of the right hind paw was defined as the MWT. All behavioral tests were performed by an investigator who was blinded to the experimental design.

Assessment of serum, colon, and liver indexes

Serum uric acid and liver XOD concentrations were measured using assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), following the manufacturer’s instructions. Colon or liver tissues were homogenized in buffer solution (0.05 g/1 mL) using a high-speed homogenizer and centrifuged at 12,000 rpm at 4 °C for 10 min. The concentrations of IL-1β, IL-6, G-CSF, and TNF-α in serum and colon supernatants were quantified using assay kits (CUSABIO, Wuhan, China), following the manufacturer’s protocols.

Gut microbiota analysis

Total genomic DNA was isolated from each stool sample using a stool DNA isolation kit (Qiagen, Hilden, Germany) and quantified using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). The qualified DNA was sequenced for the V3-V4 region of the 16 S rRNA gene using an Illumina Miseq platform (Illumina, San Diego, CA, USA) at Shanghai Personalbio Technology Co., Ltd. The raw data were deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) database (ID: PRJNA932929). Microbiome data were analyzed using the Genescloud platform (http://greengenes.secondgenome.com/). The Quantitative Insights Into Microbial Ecology (QIIME) software was used for data assembly, demultiplexing, and quality filtering. Sequences with ≥ 97% similarity were assigned to the same operational taxonomic unit (OTU), and taxonomic assignment was done using the Greengenes database. Principal Coordinates Analysis (PCoA) was conducted to compare microbiota compositions between different samples. Linear discriminant analysis effect size (LEfSe) and one-way ANOVA analysis were performed to identify statistically significant genera between the two groups.

Western blot analysis

Colon samples were homogenized in RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China), supplemented with a cocktail of protease and phosphatase inhibitor, and incubated on ice for 30 min. The homogenates were then centrifuged at 12,000×g for 10 min to obtain total proteins, and their concentrations were determined using the BCA Protein Assay Kit (Beyotime biotechnology, Shanghai, China). Subsequently, 40 µg of cell lysates were separated by SDS-PAGE on a 7.5/10% gel and transferred onto a nitrocellulose membrane (Pall Corporation, MI, USA). The membranes were blocked with 5% BSA in TBST (Tris-buffered saline with 0.1% Tween-20) at room temperature for 1 h to minimize non-specific binding sites, followed by overnight incubation with primary antibodies at 4 °C, and then incubated with the appropriate secondary antibody. The Western blot results were scanned and analyzed using an infrared imaging system (Odyssey CLx; LI-COR Biosciences). Gel quantification was performed using ImageJ software.

Commercially available antibodies were used as follows: NLRP3 (1:1000 dilution; Cell Signaling Technology, #15,101), ASC (1:1000 dilution; Cell Signaling Technology, #67,824), Caspase-1 (1:1000 dilution; Abcam, #ab179515), β-Actin (1:5000; R&D system, #MAB8929), Dylight 800, Goat anti-Rabbit IgG (1:10000 dilution; Immunoway, #RS23920), and Dylight 680, Goat anti-Mouse IgG (1:10000 dilution; Immunoway, #RS23710).

Histological analysis

Formalin-fixed colon sections of each mouse were sectioned for histopathological analysis. H&E and AB-PAS staining were used to stain the tissue sections according to the manufacturer’s instructions (Beyotime Biotechnology, Shanghai, China). The images were evaluated using ImageJ software, and the intestinal villus height, intestinal wall thickness, and goblet cell quantity were counted and compared among groups.

Statistical analysis

Statistical analyses were performed using SPSS software version 22.0. One-way ANOVA or the rank-sum test was used for data analysis based on the normality test and homogeneity of variance. P-values were adjusted using the Benjamini-Hochberg method to control the false discovery rate (FDR), and an adjusted p-value < 0.05 was considered statistically significant.

Results

Effects of Simiao decoction, allopurinol, or FMT on gut microbiota

A scatter plot based on PCoA scores (Fig. 2A) demonstrated distinct microbial compositions in the comparisons of CT vs. MT, MT vs. SM, and MT vs. FSM, with some overlap observed among MT, AP, and FAP groups. At the phylum level, gout arthritis mice had higher levels of Proteobacteria and lower levels of Bacteroidetes and Firmicutes compared to control mice (Fig. 2B). Simiao decoction and its related FMT successfully restored the dysbiosis of microbial phyla in gout arthritis mice, whereas allopurinol and its related FMT did not show any effect (Fig. 2B). Therefore, Simiao decoction had a more significant impact on gut microbiota of gout arthritis mice compared to allopurinol.

Fig. 2
figure 2

Alterations in gut microbiota induced by Simiao decoction, allopurinol, or FMT. (A) PCoA score plot of gut microbiota based on UniFrac distance matrices; (B) The percentage abundance of major phylum; Significantly different genera between CT and MT (C), between MT and SM (D), between MT and AP (E), between MT and FSM (F), and between MT and FAP (G). CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice. “**” indicates p < 0.01; “*” indicates p < 0.05. N = 6 mice/group

Full size image

Furthermore, a combination of LEfSe and one-way ANOVA analyses revealed significant differences in microbial genera between two groups. As shown in Fig. 2C, MT group had higher levels of genus Helicobacter, Mucispirillum, and Paraprevotella and a lower level of genus Prevotella than the CT group. Treatment of Simiao decoction reduced the abundances of genus Helicobacter, Alistipes, and Prevotella and increased the abundances of genus Akkermansia and Anaerotruncus in gout arthritis mice (Fig. 2D). The genera altered by Simiao decoction differed from those altered by allopurinol. Allopurinol increased the abundances of genus Parabacteroides, AF12, and Macellibacteroides and reduced the abundances of genus Lactobacillus, Clostridium, and Pseudomonas in the treatment of gout arthritis mice (Fig. 2E). In addition, FMT caused alterations in microbial genera in gout arthritis mice. The transplantation of gut microbiota derived from Simiao decoction-treated mice reduced genus Helicobacter and increased genus Parabacteroides and Akkermansia in gout arthritis mice (Fig. 2F), while the transplantation of gut microbiota derived from allopurinol-treated mice increased genus AF12, Parabacteroides, and Roseburia in gout arthritis mice (Fig. 2G).

Effects of Simiao decoction, allopurinol, or FMT on gout arthritis symptoms

Feeding a high purine diet could significantly increase serum uric acid and liver XOD activity, and the injection of MSU crystals induced foot swelling and reduced pain threshold in mice with gouty arthritis (Fig. 3). Simiao decoction and its related FMT significantly alleviated all four gout arthritis symptoms (Fig. 3). Allopurinol was also effective in reducing serum uric acid, liver XOD activity, and foot swelling in gout arthritis mice (Fig. 3A C). However, the transplantation of gut microbiota derived from allopurinol-treated mice showed no therapeutic efficiency in improving the four gout arthritis symptoms mentioned above (Fig. 3).

Fig. 3
figure 3

Differences in serum levels of uric acid (A), liver xanthine oxidase activity (B), pain threshold (C), and foot swelling (D) among different groups. CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice. “**” indicates p < 0.01; “*” indicates p < 0.05. N = 6 mice/group

Full size image

Effects of Simiao decoction, allopurinol, or FMT on serum proinflammatory cytokines

This study used serum IL-1β, IL-6, TNF-α, and G-CSF levels to assess the severity of gout arthritis in mice. As depicted in Fig. 4, gout arthritis mice had a significant upregulation of the above four proinflammatory cytokines. Simiao decoction and its related FMT significantly reduced serum levels of these cytokines (Fig. 4). Allopurinol was able to significantly decrease serum levels of IL-1β, IL-6, and G-CSF, but showed no significant effect on serum TNF-α in gout arthritis mice (Fig. 4). The transplantation of gut microbiota derived from allopurinol-treated mice did not have any noticeable effect on the aforementioned serum proinflammatory cytokines in gout arthritis mice (Fig. 4).

Fig. 4
figure 4

Differences in the levels of serum IL-1β (A), IL-6 (B), TNF-α (C), and G-CSF (D) among different groups. CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice. “**” indicates p < 0.01; “*” indicates p < 0.05. N = 6 mice/group

Full size image

Effects of Simiao decoction, allopurinol, or FMT on gut inflammation

Gut inflammation is a significant contributor to the development of gout arthritis model. As depicted in Fig. 4A and B, gout arthritis mice exhibited significantly higher concentrations of colon IL-1β and IL-6 compared to control mice. Simiao decoction and its related FMT were effective in significantly reducing the concentrations of colon IL-1β and IL-6 (Fig. 5A and B). Allopurinol showed a decreasing effect on colon IL-1β but had no significant effect on colon IL-6. However, the transplantation of gut microbiota derived from allopurinol-treated mice did not reduce the concentrations of colon IL-1β and IL-6 in gout arthritis mice (Fig. 5A and B).

Fig. 5
figure 5

Differences in the levels of IL-1β (A) and IL-6 (B) in the colon, as well as the expression of NLRP3 (C), Caspase-1 (D) and ASC (E) in the colon, were observed among the different groups. CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice. “**” indicates p < 0.01; “*” indicates p < 0.05. N = 3 mice/group

Full size image

To investigate the expression of NLRP3 inflammasome, colon samples were also collected. The NLRP3 inflammasome was activated in the colon of gout arthritis mice. Simiao decoction and its related FMT significantly reduced the production of NLRP3, caspase-1 and ASC, but allopurinol only reduced the production of ASC, and its related FMT had no significant influence on NLRP3 inflammasome in gouty arthritis mice (Fig. 5C and E, Supplementary information files).

Effects of Simiao decoction, allopurinol, and FMT on colon pathology

H&E and AB-PAS staining were utilized to assess colon pathology (Fig. 6). Histological examination indicated that gout arthritis induced significant damage to the colon tissues, as evidenced by thinning of the intestinal wall, distorted crypts, loss of goblet cells, and inflammatory cell infiltration (Fig. 6). Simiao decoction and its related FMT were able to significantly restore the damage to colon tissues, as evidenced by an increase in intestinal wall thickness, villus height, and goblet cells and a reduction in inflammatory cell infiltration (Fig. 6). However, allopurinol and its related FMT did not result in any significant repair of colon tissue damage in the gout arthritis mice (Fig. 6).

Fig. 6
figure 6

Representative images of H&E-stained and AB-PAS-stained (A) colon tissue histology is shown. Differences in colon intestinal wall thickness (B), villus height (C), and number of goblet cells (D) are observed among different groups. CT: control mice; MT: gout arthritis mice; SM: gout mice treated with Simiao decoction; AP: gout mice treated with allopurinol; FSM: gout mice transplanted with fecal microbiota from Simiao decoction-treated gout mice; FAP: gout mice transplanted with fecal microbiota from allopurinol-treated gout mice. “**” indicates p < 0.01; “*” indicates p < 0.05. N = 3 mice/group

Full size image

Discussion

In recent, intestinal dysbiosis associated with gout arthritis has been widely studied, since gut microbiota could mediate MSU crystal-induced inflammation [8] and hyperuricemia [13, 27]. Gut microbiota affects not only the activity of gout arthritis [28] but also the therapeutic effects of drugs on gout arthritis [29]. Previous studies have reported that Simiao decoction and allopurinol could induce alterations in gut microbiota during the treatment of gout [15, 24, 30]. However, there is still a lack of direct evidence confirming whether these treatments alleviate gout arthritis symptoms by regulating gut microbiota. This study used FMT to directly demonstrate that Simiao decoction could regulate gut microbiota to alleviate gout arthritis, while allopurinol does not have the same effect.

Allopurinol is recognized as a xanthine oxidase inhibitor that reduces uric acid levels. The present study indicates that allopurinol not only lowers uric acid levels but also exhibits an anti-inflammatory effect. This effect may be attributed to the drug’s ability to lower uric acid, which results in decreased urate crystal formation and less stimulation of NLRP3 inflammasome [31]. Compared to allopurinol, Simiao decoction not only had a similar uric acid-lowering effect but also demonstrated superior anti-inflammatory effect on both serum and gut inflammation. It is widely known that gout inflammation is a form of systemic inflammation that can occur in the joints, intestine, and kidney [32]. This study was limited in its capacity to observe inflammation levels within foot joint due to our failure to separate the tissues of foot joint.

Both Simiao decoction and allopurinol had an impact on gut microbiota in the treatment of gout arthritis mice. The PCoA analysis indicated the effect of Simiao decoction was greater than that of allopurinol in treating gout arthritis mice. The differences between the two treatments were also reflected by the alterations in microbial phylum and genus. At the phylum level, Simiao decoction was able to reverse the increase of phylum Proteobacteria in gout arthritis mice, while allopurinol had no such effect. Phylum Proteobacteria is considered a biomarker of the “pro-inflammatory” state of the host [33, 34] and has been found to be significantly elevated in gout patients compared to healthy individuals [35, 36]. At the genus level, while the number of genera altered by Simiao decoction was similar to that altered by allopurinol, Simiao decoction significantly altered the dominant genus Helicobacter in gout arthritis mice. Genus Helicobacter has been increasingly recognized as emerging pathogens over decades [37] and has been associated with the development of various diseases such as inflammatory bowel disease [38], colorectal cancer [39], and irritable bowel syndrome [40]. A significant increase in genus Helicobacter was observed in gout arthritis mice, while Simiao decoction was able to reduce its abundance. Genus Helicobacter might aggravate gout arthritis by activating NLRP3 inflammasome [41]. Furthermore, Simiao decoction reduced the abundances of genus Alistipes and Prevotella while increasing the abundance of genus Akkermansia and Anaerotruncus. Both Alistipes and Prevotella have been found to be dysregulated in gout patients [5, 42] and have been implicated in promoting chronic inflammation [43, 44]. The underlying mechanism of Prevotella in inducing gout inflammation might be by enhancing IL-1b production through activating NLRP3 inflammasome [45]. The increases in Akkermansia and Anaerotruncus might represent a protective mechanism associated with recovery from the disease and are not part of the pathogenic mechanism that induces or maintains the disease [46, 47]. In addition, genus Akkermansia could effectively attenuate hyperuricemia by regulating uric acid metabolism and inflammation [48]. Some of the genera altered by allopurinol have also been reported to be associated with gout arthritis, including Clostridium [49] and Lactobacillus [50]. However, these genera accounted for a relatively small proportion of gut microbiota in gout arthritis mice.

Subsequently, this study performed FMT to investigate whether the therapeutic effects of Simiao decoction and allopurinol on gout arthritis were mediated by gut microbiota modulation. FMT was used to determine whether the drugs exerted their therapeutic effects by modulating gut microbiota [27, 51, 52]. Results showed that FMT from Simiao decoction-treated gout mice was able to alleviate gout arthritis symptoms, whereas transplantation of gut microbiota from allopurinol-treated gout mice had no therapeutic effect. This may be due to the fact that transplantation of gut microbiota from Simiao decoction-treated gout mice was able to decrease the abundance of genus Helicobacter and increase the abundance of genus Akkermansia, which are associated with beneficial effects. On the other hand, FMT from allopurinol-treated gout arthritis mice did not significantly alter the abundance of genus Helicobacter or other gout-associated genera.

Conclusion

To summarize, our data demonstrated that Simiao decoction can alleviate gout arthritis symptoms by modulating gut microbiota. This study provides direct evidence that gut microbiota can be a mechanism of traditional Chinese medicine in treating diseases. However, the findings have not been confirmed with human samples, and the underlying mechanisms from the host’s perspective have not been elucidated. Nonetheless, this research could advance our understanding of the therapeutic mechanisms of Simiao decoction.

Data Availability

Raw sequencing reads of 16 S rRNA sequencing described have been deposited in the NCBI Sequence Read Archive under accession number: PRJNA932929. Further information and requests for resources and reagents should be directed to the corresponding author, Z.H. (hzx2015@zcmu.edu.cn)

Change history

References

  1. Wu M, Tian Y, Wang Q, Guo C. Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. Clin Rheumatol. 2020;39:2849–59.

    PubMed  Google Scholar 

  2. Huang J, Ma ZF, Tian Y, Lee YY. Epidemiology and prevalence of gout in Mainland China: an updated systematic review and meta-analysis. SN Compr Clin Med. 2020;2:1593–606.

    Google Scholar 

  3. Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2011;63:238–45.

    Google Scholar 

  4. Busso N, So A. Gout. Mechanisms of inflammation in gout. Arthritis Res therapy. 2010;12:1–8.

    Google Scholar 

  5. Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q, Su X, Qiao J, Zheng Y, Wang L. Intestinal microbiota distinguish gout patients from healthy humans. Sci Rep. 2016;6:1–10.

    Google Scholar 

  6. Shao T, Shao L, Li H, Xie Z, He Z, Wen C. Combined signature of the fecal microbiome and metabolome in patients with gout. Front Microbiol. 2017;8:268.

    PubMed  PubMed Central  Google Scholar 

  7. Lin X, Shao T, Wen X, Wang M, Wen C, He Z. Combined effects of MSU crystals injection and high fat-diet feeding on the establishment of a gout model in C57BL/6 mice. Adv Rheumatol 2020, 60.

  8. Vieira AT, Macia L, Galvão I, Martins FS, Canesso MCC, Amaral FA, Garcia CC, Maslowski KM, De Leon E, Shim D. A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis & Rheumatology. 2015;67:1646–56.

    CAS  Google Scholar 

  9. Vieira A, Galvao I, Amaral F, Teixeira M, Nicoli J, Martins F. Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. Beneficial microbes. 2015;6:799–806.

    CAS  PubMed  Google Scholar 

  10. Prasad C, Iqbal U, Westfall S, Prakash S, MANAGEMENT OF HYPERURICEMIA AND GOUT BY PREBIOTICS AND PROBIOTICS. : POTENTIALS AND LIMITATIONS. Int J Probiotics Prebiotics 2017, 12.

  11. Shen H, Guan Q, Zhang X, Yuan C, Tan Z, Zhai L, Hao Y, Gu Y, Han C. New mechanism of neuroinflammation in Alzheimer’s disease: the activation of NLRP3 inflammasome mediated by gut microbiota. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109884.

    CAS  PubMed  Google Scholar 

  12. Li X, He C, Li N, Ding L, Chen H, Wan J, Yang X, Xia L, He W, Xiong H. The interplay between the gut microbiota and NLRP3 activation affects the severity of acute pancreatitis in mice. Gut Microbes. 2020;11:1774–89.

    PubMed  PubMed Central  Google Scholar 

  13. Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu X, Cai L, Feng F. The gut microbiota as a target to control hyperuricemia pathogenesis: potential mechanisms and therapeutic strategies. Crit Rev Food Sci Nutr. 2022;62:3979–89.

    CAS  PubMed  Google Scholar 

  14. Sato K, Yamazaki K, Kato T, Nakanishi Y, Tsuzuno T, Yokoji-Takeuchi M, Yamada-Hara M, Miura N, Okuda S, Ohno H. Obesity-related gut microbiota aggravates alveolar bone destruction in experimental periodontitis through elevation of uric acid. MBio. 2021;12:e00771–00721.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the gut microbiome associated with the treatment of hyperuricaemia in male rats. Front Microbiol. 2018;9:2233.

    PubMed  PubMed Central  Google Scholar 

  16. Park H-K, Lee SJ. Treatment of gouty arthritis is associated with restoring the gut microbiota and promoting the production of short-chain fatty acids. Arthritis Res Therapy. 2022;24:51.

    CAS  Google Scholar 

  17. Liu Y-F, Huang Y, Wen C-Y-Z, Zhang J-J, Xing G-L, Tu S-H, Chen Z. The effects of modified simiao decoction in the treatment of gouty arthritis: a systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine 2017, 2017.

  18. Wang H, Duan H, Chen S, Luo Y, Zhang Y, Liu Q, Zhang X. Chinese herbal medicine si-miao-san decoction for acute gouty arthritis: a protocol for systematic review and meta-analysis of randomized controlled trials. Medicine 2020, 99.

  19. Liang H, Deng P, Ma Y-F, Wu Y, Ma Z-H, Zhang W, Wu J-D, Qi Y-Z, Pan X-Y, Huang F-S. Advances in experimental and clinical research of the gouty arthritis treatment with traditional chinese medicine. Evidence-based Complement Altern Med. 2021;2021:1–15.

    Google Scholar 

  20. Tian R. Clinical observation on treating gouty arthritis with modified Simiao decoction and external application of traditional chinese medicine. Int J Traditional Chin Med 2014:600–3.

  21. Hua J, Huang P, Zhu C-M, Yuan X, Yu C-H. Anti-hyperuricemic and nephroprotective effects of modified Simiao Decoction in hyperuricemic mice. J Ethnopharmacol. 2012;142:248–52.

    PubMed  Google Scholar 

  22. Shui G, Cai Z, Wang F, Chen T, Huang X, Cai Y, Mi X. Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation. BMC Complement Med Ther. 2022;22:278.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Xu H, Wu J, Wang S, Xu L, Liu P, Shi Y, Wu S, Deng L, Chen X. Network pharmacology and in vivo experiments reveal the pharmacological effects and molecular mechanisms of Simiao Powder in prevention and treatment for gout. BMC Complement Med Ther. 2022;22:152.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Lin X, Shao T, Huang L, Wen X, Wang M, Wen C, He Z. Simiao decoction alleviates gouty arthritis by modulating proinflammatory cytokines and the gut ecosystem. Front Pharmacol. 2020;11:955.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Chaplan SR, Bach FW, Pogrel J, Chung J, Yaksh T. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63.

    CAS  PubMed  Google Scholar 

  26. Marcotti A, Miralles A, Dominguez E, Pascual E, Gomis A, Belmonte C, de la Peña E. Joint nociceptor nerve activity and pain in an animal model of acute gout and its modulation by intra-articular hyaluronan. Pain. 2018;159:739.

    PubMed  PubMed Central  Google Scholar 

  27. Wu J, Wei Z, Cheng P, Qian C, Xu F, Yang Y, Wang A, Chen W, Sun Z, Lu Y. Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis. Theranostics. 2020;10:10665.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Xie W-R, Yang X-Y, Deng Z-H, Zheng Y-M, Zhang R, Wu L-H, Cai J-Y, Kong L-P, Xia HH-X, He X-X. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with acute and recurrent gout: a pilot study. Dig Dis. 2022;40:684–90.

    PubMed  Google Scholar 

  29. Tong S, Zhang P, Cheng Q, Chen M, Chen X, Wang Z, Lu X, Wu H. The role of gut microbiota in gout: is gut microbiota a potential target for gout treatment. Front Cell Infect Microbiol. 2022;12:1786.

    Google Scholar 

  30. Kondratiuk VE, Tarasenko OM, Karmazina OM, Taranchuk VV. Impact of the synbiotics and urate-lowering therapy on gut microbiota and cytokine profile in patients with chronic gouty arthritis. J Med Life. 2020;13:490.

    PubMed  PubMed Central  Google Scholar 

  31. Schlesinger N, Brunetti L. Beyond urate lowering: analgesic and anti-inflammatory properties of allopurinol. Seminars in arthritis and rheumatism. Elsevier; 2020: 444–50.

  32. Zhou X, Zhang B, Zhao X, Lin Y, Wang J, Wang X, Hu N, Wang S. Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. Food Funct. 2021;12:5637–49.

    CAS  PubMed  Google Scholar 

  33. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD—what role do Proteobacteria play? Nat reviews Gastroenterol Hepatol. 2012;9:219–30.

    CAS  Google Scholar 

  34. Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, Aitken JD, Su Y, Chassaing B, Walters WA, González A. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe. 2012;12:139–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Méndez-Salazar EO, Vázquez-Mellado J, Casimiro-Soriguer CS, Dopazo J, Çubuk C, Zamudio-Cuevas Y, Francisco-Balderas A, Martínez-Flores K, Fernández-Torres J, Lozada-Pérez C. Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism. Mol Med. 2021;27:1–13.

    Google Scholar 

  36. Yuan X, Chen R, Zhang Y, Lin X, Yang X. Altered gut microbiota in children with hyperuricemia. Front Endocrinol 2022, 13.

  37. Ochoa S, Collado L. Enterohepatic Helicobacter species–clinical importance, host range, and zoonotic potential. Crit Rev Microbiol. 2021;47:728–61.

    CAS  PubMed  Google Scholar 

  38. Hansen R, Thomson JM, Fox JG, El-Omar EM, Hold GL. Could Helicobacter organisms cause inflammatory bowel disease? FEMS Immunol Med Microbiol. 2011;61:1–14.

    CAS  PubMed  Google Scholar 

  39. Butt J, Epplein M. Helicobacter pylori and colorectal cancer—A bacterium going abroad? PLoS Pathog. 2019;15:e1007861.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Yakoob J, Abbas Z, Naz S, Islam M, Jafri W. Virulence markers of Helicobacter pylori in patients with diarrhoea-dominant irritable bowel syndrome. Br J Biomed Sci. 2012;69:6–10.

    CAS  PubMed  Google Scholar 

  41. Engler DB, Leonardi I, Hartung ML, Kyburz A, Spath S, Becher B, Rogler G, Müller A. Helicobacter pylori–specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis. 2015;21:854–61.

    PubMed  Google Scholar 

  42. Chu Y, Sun S, Huang Y, Gao Q, Xie X, Wang P, Li J, Liang L, He X, Jiang Y. Metagenomic analysis revealed the potential role of gut microbiome in gout. npj Biofilms and Microbiomes. 2021;7:66.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Parker BJ, Wearsch PA, Veloo AC, Rodriguez-Palacios A. The genus Alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151:363–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Jang H-M, Park J-Y, Lee Y-J, Kang M-J, Jo S-G, Jeong Y-J, Cho N-P, Cho S-D, Kim D-J, Park J-H. TLR2 and the NLRP3 inflammasome mediate IL-1β production in Prevotella nigrescens-infected dendritic cells. Int J Med Sci. 2021;18:432.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Bianchimano P, Britton GJ, Wallach DS, Smith EM, Cox LM, Liu S, Iwanowski K, Weiner HL, Faith JJ, Clemente JC. Mining the microbiota to identify gut commensals modulating neuroinflammation in a mouse model of multiple sclerosis. Microbiome. 2022;10:174.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Geerlings SY, Kostopoulos I, De Vos WM, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: when, where, and how? Microorganisms. 2018;6:75.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhang L, Liu J, Jin T, Qin N, Ren X, Xia X. Live and pasteurized Akkermansia muciniphila attenuate hyperuricemia in mice through modulating uric acid metabolism, inflammation, and gut microbiota. Food Funct. 2022;13:12412–25.

    CAS  PubMed  Google Scholar 

  49. Xing S-C, Meng D-M, Chen Y, Jiang G, Liu X-S, Li N, Yan Y-Y, Li C-G. Study on the diversity of Bacteroides and Clostridium in patients with primary gout. Cell Biochem Biophys. 2015;71:707–15.

    CAS  PubMed  Google Scholar 

  50. Yamanaka H, Taniguchi A, Tsuboi H, Kano H, Asami Y. Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: a randomised, double-blind, placebo-controlled study. Mod Rheumatol. 2019;29:146–50.

    CAS  PubMed  Google Scholar 

  51. Dong S, Zhu M, Wang K, Zhao X, Hu L, Jing W, Lu H, Wang S. Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacol Res. 2021;171:105767.

    CAS  PubMed  Google Scholar 

  52. Huang S, Hu S, Liu S, Tang B, Liu Y, Tang L, Lei Y, Zhong L, Yang S, He S. Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner. Pharmacol Res. 2022;175:105992.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the Natural Science Foundation of Zhejiang Province (No. LY21H270006).

Author information

Authors and Affiliations

  1. Department of Plastic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China

    Xiaoying Lin

  2. Institute of Basic Research in Clinical Medicine, School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China

    Xiaoying Lin, Mingzhu Wang & Zhixing He

  3. Center for General Practice Medicine, Department of Rheumatology and Immunology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, 310014, China

    Guifeng Hao

Authors
  1. Xiaoying Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingzhu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhixing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guifeng Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XL, ZH and GH contributed toward conceiving the research. XL conducted animal experiments. MW, ZH and GH assisted in conducting the experiments. ZH and GH analyzed the data and drafted the manuscript. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Zhixing He or Guifeng Hao.

Ethics declarations

Ethics approval and consent to participate

The approved protocols for the animal study were obtained from the Animal Ethics Committee of Zhejiang Chinese Medical University (protocol number: 20210816-12). All protocols in this study were carried out in accordance with relevant guidelines and regulations for using animals in compliance with the ARRIVE guidelines (https://arriveguidelines.org).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: “The authors identified an error in the affiliation of author name Guifeng Hao. The incorrect author affiliation is: Guifeng Hao2,3. The correct author affiliation is: Guifeng Hao3.”

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lin, X., Wang, M., He, Z. et al. Gut microbiota mediated the therapeutic efficiency of Simiao decoction in the treatment of gout arthritis mice. BMC Complement Med Ther 23, 206 (2023). https://doi.org/10.1186/s12906-023-04042-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-023-04042-4

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us